Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :29899095
Publication Date : //

Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge.


Broadly cross-reactive antibodies (Abs) that recognize conserved epitopes within the influenza virus hemagglutinin (HA) stalk domain are of particular interest for their potential use as therapeutic and prophylactic agents against multiple influenza virus subtypes, including zoonotic virus strains. Here, we characterized four human HA stalk-reactive monoclonal antibodies (MAbs) for their binding breadth and affinity, neutralization capacity, and protective potential against an highly pathogenic avian influenza virus. The monoclonal antibodies were isolated from individuals shortly following infection with (70-1F02 and 1009-3B05) or vaccination against (05-2G02 and 09-3A01) A(H1N1)pdm09. Three of the MAbs bound HAs from multiple strains of group 1 viruses, and one MAb, 05-2G02, bound to both group 1 and group 2 influenza A virus HAs. All four antibodies prophylactically protected mice against a lethal challenge with the highly pathogenic A/Vietnam/1203/04 (H5N1) strain. Two MAbs, 70-1F02 and 09-3A01, were further tested for their therapeutic efficacy against the same strain and showed good efficacy in this setting as well. One MAb, 70-1F02, cocrystallized with H5 HA and showed heavy-chain-only interactions similar to those seen with the previously described CR6261 anti-stalk antibody. Finally, we show that antibodies that compete with these MAbs are prevalent in serum from an individual recently infected with the A(H1N1)pdm09 virus. The antibodies described here can be developed into broad-spectrum antiviral therapeutics that could be used to combat infections by zoonotic or emerging pandemic influenza viruses. The rise in zoonotic infections of humans by emerging influenza viruses is a worldwide public health concern. The majority of recent zoonotic human influenza cases were caused by H7N9 and H5Nx viruses and were associated with high morbidity and mortality. In addition, seasonal influenza viruses are estimated to cause up to 650,000 deaths annually worldwide. Currently available antiviral treatment options include only neuraminidase inhibitors, but some influenza viruses are naturally resistant to these drugs, and others quickly develop resistance-conferring mutations. Alternative therapeutics are urgently needed. Broadly protective antibodies that target the conserved "stalk" domain of the hemagglutinin represent potential potent antiviral prophylactic and therapeutic agents that can assist pandemic preparedness. Here, we describe four human monoclonal antibodies that target conserved regions of influenza HA and characterize their binding spectrum as well as their protective capacity in prophylactic and therapeutic settings against a lethal challenge with a zoonotic influenza virus.

Authors : Nachbagauer Raffael , Shore David , Yang Hua , Johnson Scott K , Gabbard Jon D , Tompkins S Mark , Wrammert Jens , Wilson Patrick C , Stevens James , Ahmed Rafi , Krammer Florian , Ellebedy Ali H ,

Related products :

Catalog number Product name Quantity
11055-RM10 H1N1 Hemagglutinin Antibody (2009 Influenza Pandemic) 100
H1N1-02-A Anti-Hemagglutinin Influenza A Virus H1N1 H1 (Pan H1N1 reacts with multiple strains of H1N1) IgG Species Reactivity: Influenza Virus 100 ul Product tipe: Pure protein
H1N1-01-C Recombinant Purified Hemagglutinin Influenza A Virus H1N1 H1 (H1N1) (A_New Caledonia_20_99) protein control for Western Species Reactivity: Influenza Virus 100 ul Product tipe: Pure protein
H1N1-01-R-10 Recombinant Purified Hemagglutinin Influenza A Virus H1N1 H1 (H1N1) (A_New Caledonia_20_99) protein Species Reactivity: Influenza Virus 10 ug Product tipe: Pure protein
H1N1-01-A Anti-Hemagglutinin Influenza A Virus H1N1 H1 (H1N1) (A_New Caledonia_20_99) IgG Species Reactivity: Influenza Virus 100 ul Product tipe: Pure protein
X2558M Human Influenza A, H1N1, H2N2, H3N2, H5N1 Nucleoprotein Monoclonal Antibody 100
H5N11-C Recombinant Purified Hemagglutinin Influenza A Virus H5N1 H5 (H5N1) (A_chicken_India_NIV33487_2006) (17-531aa) protein control for Western Species Reactivity: Influenza Virus 100 ul Product tipe: Pure protein
H5N11-S Anti-Hemagglutinin Influenza A Virus H5N1 H5 (H5N1) (A_chicken_India_NIV33487_2006) (17-531aa) protein antiserum Species Reactivity: Influenza Virus 100 ul Product tipe: Antbodies
H5N15-R-10 Recombinant Purified Hemagglutinin Influenza A Virus H5N1 H5 (H5N1) (A_chicken_India_NIV33487_2006) (17-531aa), His-tag Species Reactivity: Influenza Virus 10 ug Product tipe: Pure protein
H5N15-R-100 Recombinant Purified Hemagglutinin Influenza A Virus H5N1 H5 (H5N1) (A_chicken_India_NIV33487_2006) (17-531aa), His-tag Species Reactivity: Influenza Virus 100 ug Product tipe: Pure protein
MAB - 606020170 Monoclonal Antibodies: Influenza A virus Nucleoprotein; reactive species: A_Korea_426_68(H2N2) ; Isotype: IgG1; Specificity: Influenza A virus Nucleoprotein 0.1ml
MAB - 606020171 Monoclonal Antibodies: Influenza B virus Nucleoprotein; reactive species: Stain:B_Lee_40; Clone: 1A2A11; Isotype: Mouse IgG2b; Specificity: Influenza B virus Nucleoprotein 0.1ml
FR 063 Influenza Virus (H1N1) to differentiate between seasonal H1N1 and recently outbreak human H1N1 of swine origin 100 reactions
FR063 Influenza Virus (H1N1) to differentiate between seasonal H1N1 and recently outbreak human H1N1 of swine origin 100
FR063 Influenza Virus (H1N1): to differentiate between seasonal H1N1 and recently outbreak human H1N1 of swine origin FLUORGENIC REALTIME PCR - READY TO USE KIT 100 REACTIONS
H1N1-02-A Anti-Hemagglutinin Influenza A Virus H1N1 H1 (Pan H1N1 reacts with multiple strains of H1N1) IgG 100 ul
FR063 Influenza Virus (H1N1): to differentiate between seasonal H1N1 and recently outbreak human H1N1 of swine origin ,FLUORGENIC REALTIME PCR - READY TO USE KITS, REAL TIME PCR 100 REACTIONS
orb81796 Influenza Virus H1N1 New Caledonia 20_99 IV 116 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain A_ New Caledonia_20_99 IVR 116. The Influenza Virus was 10
orb81797 Influenza Virus H1N1 Taiwan 1_86 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain A_Taiwan_1_86. The Influenza Virus was purified by Ultracentrifugation 10
orb81795 Influenza Virus H1N1 Beijing 262_95 protein Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza virus, strain A_Beijing_262_95. The Influenza Virus was purified by Ultracentrifu 10
YVS7531 Feline Rhinotracheitis Virus, Clone 7531, Mab anti_, broadly reactive 100 µg.
H1N1-01-C Recombinant Purified Hemagglutinin Influenza A Virus H1N1 H1 (H1N1) (A New Caledonia 20 99) protein control for Western 100 ul
H1N1-01-R-10 Recombinant Purified Hemagglutinin Influenza A Virus H1N1 H1 (H1N1) (A New Caledonia 20 99) protein 10 ug
OBT0874 Rabies Virus, Surface Glycoprotein, broadly reactive, Clone 6041, Mab anti_; neutralizing_ELISA_IF_IH 100 µg.
YVS6041 Rabies Virus, Surface Glycoprotein, broadly reactive, Clone 6041, Mab anti_; neutralizing 100 µg.


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur | Gentaur





GENTAUR Ltd.
Unicorn House, Station Cl
Hertfordshire, Potters Bar EN6 1TL
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017
RIB 30004 00187 00010092253 10
BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG
IBAN FR76 3000 4001 8700 0100 9225 310
france@gentaur.com | Gentaur | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur | Gentaur